Results 221 to 230 of about 178,297 (335)

SDRA par pneumonie à EBV

, 2007
Moussa Riachy, C. Baaklini, I. Ibrahim, Hiba Azar, César Yaghi, Georges Dabar, T. Bazarbachi, R Nasnas, Dolla Karam‐Sarkis, M. Germanos, N. Maacaron, Georges Khayat, Jacques Choucair   +12 more
openalex   +2 more sources

Preemptive Rituximab for Epstein–Barr Virus Reactivation after Hematopoietic Cell Transplantation: Necessary for All?

Transplant Infectious Disease, EarlyView.
A sudden increase in EBV DNAemia appears to be a better predictor of PTLD and EBV end‐organ disease than persistent and stable levels of EBV DNAemia. Most HCT recipients with EBV DNAemia did not require rituximab, and immunosuppression reduction was sufficient to control most episodes of EBV reactivation.
Anna Beatriz Coelho de Souza, Anderson João Simione, Ana Cláudia Ferrari dos Santos, Iago Colturato, Fernanda Rodrigues Barbieri, Juliana Ribeiro do Prado Moreno, Lilian Perílio Zanetti, Leila Cibele Serra de Oliveira, Erika Rodrigues Pontes Delattre, Juliana Silva Santos, Mair Pedro de Souza, Vergílio A. R. Colturato, Clarisse M. Machado   +12 more
wiley   +1 more source

Profiling and functional analysis of exosomal circRNAs from EBV-associated gastric carcinoma CSCs. [PDF]

J Cancer Res Clin Oncol
Gong LP, Shao YT, Du Y, Sun LP, Tang LY, Chen JN.   +5 more
europepmc   +1 more source

Stewardship of Molecular Diagnostics in Transplant Viral Infections

Transplant Infectious Disease, EarlyView.
ABSTRACT The transplant environment requires special considerations when testing for viral infections as immunosuppression results in atypical infection profiles. Microbes otherwise considered commensals or causing mild disease can lead to severe infections in transplant environments. Therefore, guidelines tend to recommend broader microbial testing in
Scott Sugden, David Reynoso, Reema Mathew, Michael Loeffelholz   +3 more
wiley   +1 more source

EBV Infection [PDF]

, 2020
openaire   +1 more source

Acyclovir‐Resistant Herpes Simplex Virus in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Case Series

Transplant Infectious Disease, EarlyView.
This retrospective case series of acyclovir‐resistant HSV infection in pediatric patients undergoing allogeneic HSCT discusses the clinical course, associated complications, and treatment, including side effects. We propose the first algorithm for investigating and managing acyclovir‐resistant HSV infections in pediatric HSCT recipients, highlighting ...
Jenna Nunn, Ahmed Ahmed, Srividhya Senthil, Oana Mirci‐Danicar, Denise Bonney, Claire Horgan, Omima Mustafa, Robert Wynn, Malcolm Guiver, Ramya Nataraj   +9 more
wiley   +1 more source

Evaluation of Anti-BNLF2b Antibody and Epstein-Barr Virus Biomarkers for the Diagnosis of Nasopharyngeal Carcinoma: A Retrospective Study. [PDF]

Technol Cancer Res Treat
Deng H, Liu Q, Shen H, Xiao P.
europepmc   +1 more source

EBV colitis with ulcerative colitis: a double whammy [PDF]

, 2018
Muhammad Afzal, Gaurav Nigam
openalex   +1 more source

Donor–Recipient Epstein–Barr Virus Serostatus and Time‐Varying Risk of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients

Transplant Infectious Disease, EarlyView.
In a national US kidney transplant cohort, posttransplant lymphoproliferative disorder risk varied dynamically by donor–recipient Epstein–Barr virus serostatus. Donor‐positive/recipient‐negative recipients had the highest sustained risk, while donor‐negative/recipient‐negative recipients faced previously under‐recognized early risk, with PTLD strongly ...
Christie Rampersad, Seyed M. Hosseini‐Moghaddam, S. Joseph Kim   +2 more
wiley   +1 more source

The Role of Belatacept‐Use and Senescence on Infectious and Mortality Complications After Kidney Transplantation

Transplant Infectious Disease, EarlyView.
ABSTRACT Introduction Studies evaluating the incidence of infections after belatacept as a substitute for calcineurin inhibitors (CNI) or antimetabolite in kidney transplant (KT) yielded conflicting results. We compared infectious outcomes after belatacept‐use to no belatacept‐use in KT recipients.
Hareesh Singam, Abdinoor Abdi, Wyatt Tarter, Ben Langworthy, Adam Bregman, Karam M. Obeid   +5 more
wiley   +1 more source